Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture

This paper presents a systems approach to evaluating the potential of integrated continuous bioprocessing for monoclonal antibody (mAb) manufacture across a product's lifecycle from preclinical to commercial manufacture. The economic, operational, and environmental feasibility of alternative co...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, James, Coffman, Jon, Ho, Sa V., Farid, Suzanne S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Special Section on Continous Bioprocessing
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575510/
https://www.ncbi.nlm.nih.gov/pubmed/28480535
http://dx.doi.org/10.1002/btpr.2492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575510/
https://www.ncbi.nlm.nih.gov/pubmed/28480535
http://dx.doi.org/10.1002/btpr.2492

Ejemplares similares